These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 18693330)

  • 1. I am 72, had a heart attack 16 years ago, and had angioplasty at Cleveland Clinic. My LDL was over 100 and HDL was in the low 30s. I take rosuvastatin and now my LDL is below 70, but my HDL has been driven down also, to 22. I am unable to raise HDL independent of LDL. Is it more important to control LDL below 70 and let HDL find its own level?
    Heart Advis; 2008 May; 11(5):8. PubMed ID: 18693330
    [No Abstract]   [Full Text] [Related]  

  • 2. I am a 60-year-old woman with CAD. My LDL is 64 and my HDL is 72 on Zocor, but my doctor thinks Crestor may be better for me. He says it is more potent and could reduce my numbers even more. I would have to pay for this drug out-of-pocket. Do you think the additional cost would be worth it?
    Heart Advis; 2011 Oct; 14(10):8. PubMed ID: 23019718
    [No Abstract]   [Full Text] [Related]  

  • 3. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
    Jukema JW; Liem AH; Dunselman PH; van der Sloot JA; Lok DJ; Zwinderman AH
    Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk.
    Nicholls SJ; Uno K; Kataoka Y
    Expert Rev Cardiovasc Ther; 2011 Nov; 9(11):1383-90. PubMed ID: 22059787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Statin cuts cardiovascular risk in half].
    Einecke D
    MMW Fortschr Med; 2008 Dec; 150(49-50):12-3. PubMed ID: 19133364
    [No Abstract]   [Full Text] [Related]  

  • 6. High-dose statins and atherosclerosis regression.
    Port SC
    JAMA; 2006 Oct; 296(15):1836; author reply 1837. PubMed ID: 17047208
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of low-dose rosuvastatin in patients with type 2 diabetes and hypo high-density lipoprotein cholesterolaemia.
    Katabami T; Murakami M; Kobayashi S; Matsui T; Ujihara M; Takagi S; Higa M; Ichijo T; Ohta A; Tanaka Y
    J Int Med Res; 2014 Apr; 42(2):457-67. PubMed ID: 24595147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comment from the lipidologic viewpoint].
    Riesen WF
    Praxis (Bern 1994); 2009 Feb; 98(3):125-7. PubMed ID: 19180437
    [No Abstract]   [Full Text] [Related]  

  • 9. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC; Davidson MH; Kelly MT; Setze CM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial.
    Sniderman AD
    Lancet; 2009 Jul; 374(9683):25; author reply 26-7. PubMed ID: 19577690
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
    Jones PH; Davidson MH; Kashyap ML; Kelly MT; Buttler SM; Setze CM; Sleep DJ; Stolzenbach JC
    Atherosclerosis; 2009 May; 204(1):208-15. PubMed ID: 18996523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal.
    de Lorgeril M; Salen P; Abramson J; Dodin S; Hamazaki T; Kostucki W; Okuyama H; Pavy B; Rabaeus M
    Arch Intern Med; 2010 Jun; 170(12):1032-6. PubMed ID: 20585068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exaggerated benefits of rosuvastatin compared with other statins.
    Qizilbash N
    Pharmacoepidemiol Drug Saf; 2009 May; 18(5):425-6. PubMed ID: 19382149
    [No Abstract]   [Full Text] [Related]  

  • 14. [Lipid lowering by rosuvastatin: how do statins differ?].
    Laufs U
    Dtsch Med Wochenschr; 2015 Mar; 140(5):313. PubMed ID: 25734669
    [No Abstract]   [Full Text] [Related]  

  • 15. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of atorvastatin, pitavastatin and rosuvastatin for residual cardiovascular risk using non-fasting blood sampling.
    Kakuda H; Matoba M; Nakatoh H; Nagao S; Takekoshi N
    Scand J Clin Lab Invest; 2014 Jun; 74(4):285-95. PubMed ID: 24564634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA.
    Barrios V; Escobar C
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1317-27. PubMed ID: 19900015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial.
    Rosenstein R; Parra D
    Lancet; 2009 Jul; 374(9683):25; author reply 26-7. PubMed ID: 19577689
    [No Abstract]   [Full Text] [Related]  

  • 20. Rosuvastatin and primary cardiovascular prevention. Continue to use pravastatin or simvastatin.
    Prescrire Int; 2011 Apr; 20(115):94. PubMed ID: 21648210
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.